BioMarin

This account is verified because it's an official organization on X. Learn more

@BioMarin

A leading, global rare disease biotech company focused on delivering medicines for people living with genetically defined conditions. bit.ly/3YZNeET

biomarin.com Joined June 2009

1 Following 836 Followers 229 Posts

Latest posts 5

Pinned post

BioMarin @BioMarin Dec 19, 2024

At BioMarin, we are driven by our purpose: to be the biotech leader that translates the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The BioMarin 8 – our core Operating Principles – provide the framework for how we work together every day to fulfill that purpose.

1:06

BioMarin @BioMarin 6d

Several of our team members were on hand in Cambridge, MA last week as local startups made their case for a @LabCentral Golden Ticket, which provides emerging biotechs with residency at LabCentral and access to its innovative community and resources. Orthrus Therapeutics took home the BioMarin-sponsored Golden Ticket after demonstrating a promising novel approach to help enable long-lasting immune tolerance to chronically administered therapies.

We’re proud to support Lab Central’s Golden Ticket program for the sixth consecutive year to celebrate collaboration in advancing the life sciences, and are excited to see how Orthrus Therapeutics contributes to the future of genetic medicine.

Learn more about the LabCentral Golden Ticket program: ms.spr.ly/6014afCyu

BioMarin @BioMarin Nov 2

Today we announced Q3 2026 results to the investor community, including a 32% year-over-year increase in total revenues compared to the same quarter last year. This was driven by strong underlying demand for our medicines around the world.

Read more in our press release: ms.spr.ly/6012aNoIG

$BMRN

1:01

BioMarin @BioMarin Oct 30

We’re looking forward to sharing an update with investors on our Q3 results Monday, Nov. 2 at 4:30 p.m. ET / 1:30 p.m. PT. Join our earnings call and webcast here: ms.spr.ly/6011aFY2J

$BMRN

0:12

BioMarin @BioMarin Oct 29

Today we announced we have entered into an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm to develop and commercialize a potential next-generation enzyme replacement therapy for Fabry disease. The investigational long-acting medicine is currently being studied in a Phase 1/2 clinical trial and has the potential to be the first subcutaneous enzyme replacement therapy for Fabry disease.

Read more in our press release: ms.spr.ly/6018a0q26

0:21